Katherine A. Blackwell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katherine A. Blackwell has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ariadna Forray
Department of Psychiatry, Yale School of Medicine, New Haven, USA
3 shared publications - Kimberly Ann Yonkers
Yale School of Medicine
3 shared publications - Janis Glover
Harvey Cushing/John Hay Whitney Medical Library, Yale University, 333 Cedar Street, New Haven, CT 06520-8014 USA
1 shared publication
Latest Publications
- 14 April 2015
- Published by Springer Nature
- p. 1253-1257
Perinatal Use of Antidepressants
- 28 March 2014
- Published by Annual Reviews in Annual Review of Clinical Psychology
- Vol. 10 (1) , 369-392
Antidepressant Use in Pregnant and Postpartum Women
Women in their reproductive years are at risk of experiencing depressive and anxiety disorders. As such, it is likely that pregnant women will undergo treatment with antidepressants. We review the risk of adverse birth outcomes and neonatal complications subsequent to antidepressant use in pregnancy. An inconsistent literature shows that antidepressant exposure is associated with shortened gestations and diminished fetal growth; these effects are small. Transitory neonatal signs are seen in some neonates after exposure to antidepressants in utero. No specific pattern of malformations has been consistently associated with antidepressants, with the possible exception of paroxetine and cardiac malformations. There is inconclusive evidence of a link between antidepressants in late pregnancy and persistent pulmonary hypertension in the newborn. Extensive study finds that antidepressants cannot be considered major teratogens. It is likely that confounding factors contribute to a number of the adverse effects found to be associated with antidepressant use in pregnancy.
- 28 March 2014
- Published by Annual Reviews in Annual Review of Clinical Psychology
- Vol. 10 (1) , 369-392
Antidepressant Use in Pregnant and Postpartum Women
Women in their reproductive years are at risk of experiencing depressive and anxiety disorders. As such, it is likely that pregnant women will undergo treatment with antidepressants. We review the risk of adverse birth outcomes and neonatal complications subsequent to antidepressant use in pregnancy. An inconsistent literature shows that antidepressant exposure is associated with shortened gestations and diminished fetal growth; these effects are small. Transitory neonatal signs are seen in some neonates after exposure to antidepressants in utero. No specific pattern of malformations has been consistently associated with antidepressants, with the possible exception of paroxetine and cardiac malformations. There is inconclusive evidence of a link between antidepressants in late pregnancy and persistent pulmonary hypertension in the newborn. Extensive study finds that antidepressants cannot be considered major teratogens. It is likely that confounding factors contribute to a number of the adverse effects found to be associated with antidepressant use in pregnancy.
- 1 January 2013
- Published by Springer Nature
- p. 1-6
Perinatal Use of Antidepressants